We recently published our article Top 5 Heavily Shorted Small-Cap and Mid-Cap Stocks to Buy Today. To read the full story, you can go directly to  Top 10 Heavily Shorted Small-Cap and Mid-Cap Stocks to Buy Today. In this article, we discuss ImmunityBio Inc. (NASDAQ:IBRX) as one of the stocks gaining attention, and here’s a closer look at why it stands out in today’s market.

There is something oddly fascinating about Wall Street’s most shorted stocks. They are not always the cleanest stories. They are not always the safest investments. In fact, many of them are heavily shorted precisely because investors see problems, risks, weak balance sheets, slowing growth, stretched valuations, or business models that still need to prove themselves. But that is also what makes them interesting. In the stock market, some of the biggest surprises often come from the names that investors love to doubt.

That is the setup behind this list of the 10 most shorted mid-cap and small-cap stocks to buy today. These are not just ordinary small-cap stocks or forgotten mid-cap stocks sitting quietly on the sidelines. These are companies with unusually high short interest, meaningful upside potential, and enough market attention to attract both aggressive traders and long-term investors looking for overlooked opportunities. In simpler terms, these are stocks where Wall Street disagreement is loud, visible, and potentially profitable for those who get the story right.

The timing is also important. Small-cap and mid-cap stocks have been gaining fresh attention in the first half of 2026 as investors begin rotating away from the same mega-cap technology stocks that dominated market headlines for years. After a long period where giant tech companies carried much of the broader stock market rally, money has started flowing into smaller companies with cheaper valuations, stronger recovery potential, and room for faster earnings acceleration. That shift has helped the Russell 2000 Index climb about 18%, nearly double the roughly 9% gain posted by the S&P 500 over the same period.

For investors searching for the best small-cap stocks to buy now, top mid-cap stocks with upside potential, heavily shorted stocks, short squeeze stocks, and undervalued small-cap stocks, that kind of market rotation matters. It suggests that the rally may finally be spreading beyond a small group of mega-cap winners. And when market breadth improves, smaller stocks often become more exciting because they can move faster than large, mature companies once sentiment changes.

The Wall Street Trivia Behind Short Interest

Short interest is one of those stock market terms that sounds complicated but is actually easy to understand. When investors short a stock, they are betting that its price will fall. They borrow shares, sell them, and hope to buy them back later at a lower price. If the stock drops, they profit. If the stock rises, they can lose money quickly.

That is where the drama begins.

A stock with high short interest can become explosive if good news forces short sellers to cover their positions. This means they must buy back shares, and that buying pressure can push the stock even higher. That is the basic fuel behind a short squeeze. It is also why searches for most shorted stocks to buy, best short squeeze stocks, small-cap short squeeze candidates, and high short interest stocks with upside tend to spike when risk appetite improves.

One useful trivia point: shorted stocks are not automatically bad stocks. Sometimes short sellers are correct, especially when a company has weak fundamentals, falling revenue, excessive debt, or a business model that depends too heavily on future funding. But sometimes the market becomes too pessimistic. When that happens, even a modest improvement in earnings, guidance, financing conditions, or investor sentiment can cause a heavily shorted stock to rally sharply.

That is the balancing act in this article. The goal is not to pretend that every heavily shorted small-cap or mid-cap stock is a hidden gem. That would be reckless. The smarter approach is to look for names where the bearish pressure is already obvious, but the upside potential remains large enough to deserve attention.

Why Small-Cap and Mid-Cap Stocks Are Having a Moment

Small-cap stocks and mid-cap stocks are often called the “risk-on” corner of the market. They tend to perform best when investors feel confident about economic growth, credit conditions, and corporate earnings. They can also suffer more when interest rates are high, financing becomes expensive, or investors become defensive.

That is why the current rally is worth watching. After years of underperformance versus mega-cap stocks, smaller companies are beginning to look more attractive on a valuation basis. Many mid-cap and small-cap stocks still trade at discounts compared with larger companies, giving investors a reason to hunt for bargains outside the usual blue-chip names.

There is also a simple but powerful reason investors like smaller companies: growth runway. A giant company worth hundreds of billions of dollars needs massive new revenue streams to move the needle. A small-cap company, by contrast, can sometimes transform its valuation with one strong product cycle, one major contract, one earnings inflection, one regulatory win, or one strategic turnaround. That is why the best small-cap stocks can deliver outsized returns when the business begins moving in the right direction.

Of course, this is not a free lunch. Smaller companies can also be more fragile. They may have weaker profitability, higher debt, narrower customer bases, limited access to capital, or heavier exposure to economic slowdowns. This is one reason some investors remain cautious despite the recent momentum in the Russell 2000. Wells Fargo Investment Institute analyst Alex Sagal has warned that the small-cap rally may be hiding weakness in underlying fundamentals, particularly in companies with lower profitability and heavier balance sheet pressure.

That warning deserves attention. The best investors do not just chase price movement. They ask whether the move is supported by earnings, cash flow, balance sheet strength, industry demand, and realistic growth prospects. This is especially important when dealing with the most shorted small-cap stocks and most shorted mid-cap stocks, because high short interest often exists for a reason.

The Tug-of-War Between Bulls and Bears

The most interesting part of this story is the tug-of-war. On one side are short sellers betting that these companies still have problems. On the other side are investors looking at valuation, upside targets, hedge fund interest, and improving market conditions. That tension is what makes heavily shorted stocks so compelling.

In many cases, heavily shorted mid-cap and small-cap stocks sit at the center of a very divided market opinion. The bearish argument may focus on debt, losses, competitive pressure, slowing sales, dilution risk, or uncertain demand. The bullish argument may focus on improving fundamentals, better earnings visibility, industry tailwinds, analyst price targets, insider confidence, hedge fund ownership, or the possibility of a short squeeze.

That disagreement can create opportunity, but it can also create danger. Stocks with high short float can move violently in both directions. A positive earnings report can send the stock higher as bears cover. A disappointing update can push the stock lower as short sellers gain confidence. That is why investors need to treat this category seriously. These are not sleepy dividend stocks. They are volatile names where timing, risk management, and research matter.

For readers searching for stocks with high short interest, small-cap stocks with high upside, mid-cap stocks to buy now, short squeeze stocks 2026, and hedge fund small-cap stocks, the key is to separate excitement from evidence. A stock being heavily shorted is not enough. A stock having upside potential is not enough. The better setup is when high short interest meets a credible business case, improving fundamentals, and a clear reason the market could reconsider its view.

How This List Was Built

To identify the 10 most shorted mid-cap and small-cap stocks to buy now, the screening process focused on companies with significant short interest, with priority given to stocks showing a short float of 20% or higher. The universe was then narrowed to small-cap and mid-cap companies with market capitalizations between $300 million and $10 billion.

From there, the list focused on stocks with more than 20% upside potential, based on market data as of June 2, 2026. The final group was also filtered based on popularity among elite hedge funds as of the first quarter of 2026. That extra layer matters because hedge fund interest can sometimes signal that professional investors see value, even in names that the broader market is aggressively betting against.

The final ranking is based on upside potential. That means the companies at the top are not necessarily the safest, cleanest, or most fundamentally perfect stocks. Instead, they are the heavily shorted small-cap and mid-cap stocks where the gap between current price and potential upside appears most striking.

Why Investors Should Read This List Carefully

This article is not about blindly chasing the most shorted stocks. That is how investors get burned. A high short interest stock can become a short squeeze candidate, but it can also be a value trap. The difference usually comes down to whether the company has a real path to better results.

That is why this list should be read with both curiosity and caution. The stocks featured here may appeal to investors looking for aggressive opportunities in the small-cap and mid-cap space, especially at a time when market leadership is broadening beyond mega-cap technology. But these stocks also come with real risks, including volatility, earnings uncertainty, interest rate sensitivity, debt pressure, and sharp sentiment swings.

Still, this is exactly why the category is attracting attention. The market loves a comeback story. It loves a stock that is doubted, discounted, and dismissed—until the numbers begin to change. In 2026, with small-cap and mid-cap stocks finally showing signs of life, the most shorted names may offer some of the most dramatic setups on Wall Street.

The big question now is simple: are these heavily shorted stocks warning signs, or are they misunderstood opportunities hiding in plain sight? That is what this list of the 10 most shorted mid-cap and small-cap stocks to buy today aims to explore.

CHECK THIS OUT: Top 10 Stocks Delivering Big-Time Gains Today andTop 10 Cheap Large-Cap Stocks Under $100 to Buy Now.

Our Methodology

To rank the top 10 heavily shorted small-cap and mid-cap stocks to buy today, we screened for companies with high short interest, mainly those with a short float of 20% or higher, market caps between $300 million and $10 billion, and estimated upside potential above 20% as of June 2, 2026. We then narrowed the list further by considering hedge fund interest as of Q1 2026 and ranked the final stocks primarily based on upside potential.

Top 5 Heavily Shorted Small-Cap and Mid-Cap Stocks to Buy Today

3. ImmunityBio Inc. (NASDAQ:IBRX)

Short Float: 35.30%
Market Cap: $7.58 Billion
Stock Upside Potential: 79.39%

ImmunityBio Inc. (NASDAQ: IBRX) takes the No. 3 spot with a short float of 35.30%, a market capitalization of $7.58 billion, and upside potential of 79.39%. This is one of the bigger market-cap names in the ranking, but it still fits the theme because it is heavily shorted and carries meaningful upside potential. For investors searching for most shorted biotech stocks, cancer immunotherapy stocks, small-cap and mid-cap healthcare stocks, FDA catalyst stocks, and biotech stocks to buy now, IBRX has one of the more attention-grabbing setups.

The key development came on May 19, when ImmunityBio confirmed that the U.S. Food and Drug Administration accepted for review the supplemental Biologics License Application, or sBLA, for ANKTIVA plus BCG in BCG-unresponsive non-muscle invasive bladder cancer. That is a serious regulatory milestone because FDA review can change investor sentiment quickly, especially in oncology stocks where approved indications and label expansions can directly affect commercial opportunity.

The supplemental BLA was accepted based on additional scientific data that ImmunityBio provided to the FDA. The data detailed overlapping features of papillary and CIS disease, supporting the potential expansion of ANKTIVA’s already approved indication for patients with BCG-unresponsive NMIBC with papillary tumors. In plain English, the company is trying to widen the use case for an already important bladder cancer therapy. For biotech investors, that matters because label expansion can sometimes be more commercially practical than starting from scratch with a completely unproven drug.

ImmunityBio is a clinical-stage biotechnology company developing next-generation immunotherapies and cell therapies designed to activate a patient’s immune system to fight cancer and infectious diseases. Its broader goal is to stimulate both innate and adaptive immune systems to generate long-lasting immunological memory. That scientific positioning puts IBRX directly in the center of major investment themes, including immunotherapy stocks, cell therapy stocks, oncology stocks, and innovative cancer treatment stocks.

Another important part of the story is cost savings. At the International Society for Pharmacoeconomics and Outcomes Research 2026 conference, ImmunityBio detailed the potential cost savings of ANKTIVA in the treatment of non-muscle-invasive bladder cancer patients with carcinoma in situ. According to the provided information, ANKTIVA plus BCG showed cost savings per cystectomy of $109,622 at Year 1, $151,438 at Year 2, and $60,393 at Year 3 compared to TAR-200. Those savings reportedly came from lower drug acquisition and administration costs.

That detail is not just trivia. In healthcare investing, clinical efficacy is important, but economics also matter. Hospitals, insurers, physicians, and healthcare systems increasingly care about cost-effectiveness, especially in cancer treatment where therapies can become extremely expensive. If a therapy can show both clinical value and potential economic advantages, investors may view the commercial story more favorably.

Of course, IBRX is not without risk. A 35.30% short float is not accidental. Short sellers may be focused on regulatory uncertainty, commercial execution, cash needs, competition, or valuation concerns. Biotech stocks can also move sharply based on FDA decisions, label language, trial updates, and reimbursement assumptions. That volatility is part of the reason IBRX remains one of the most debated high short interest stocks in the healthcare space.

Still, with 79.39% upside potential and 25 hedge fund holders, ImmunityBio remains a serious name on this list. It has an FDA review story, an approved product expansion angle, immunotherapy relevance, and a large cancer market connection. For investors looking for heavily shorted stocks with major upside, IBRX is not a quiet name. It is a stock with a clear catalyst and a very visible bull-versus-bear debate.

YOU MUST READ THIS: Top 10 Stocks That Could Explode 100%.

Disclosure: No material interests to disclose. This article was originally published on Global Market Bulletin.